Perspectives on Platelet Heterogeneity and Host Immune Response in Coronavirus Disease 2019 (COVID-19)

Iván Parra-Izquierdo, PhD1,2  Joseph E. Aslan, PhD1,2,3

1Knight Cardiovascular Institute, Division of Cardiology, Department of Medicine, School of Medicine, Oregon Health and Science University, Portland, Oregon
2Department of Biomedical Engineering, School of Medicine, Oregon Health and Science University, Portland, Oregon
3Department of Chemical Physiology and Biochemistry, School of Medicine, Oregon Health and Science University, Portland, Oregon

Address for correspondence Joseph E. Aslan, Knight Cardiovascular Institute, Division of Cardiology, Department of Medicine, School of Medicine, Oregon Health and Science University, 3303 SW Bond Avenue, Mail code CH13B, Oregon Health & Science University, Portland, OR 97239 (e-mail: aslanj@ohsu.edu).


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) represent a global pandemic with largely uncharacterized but dire public health consequences. COVID-19 is now increasingly recognized as a thromboinflammatory disease, where thrombotic coagulopathy and intravascular coagulation are closely linked to mortality and clinical outcomes.1–4 As thrombocytopenia, systemic microvascular thrombosis, and elevated D-dimer levels reflect COVID-19 severity,1–4 cellular effectors of hemostasis and thrombosis—especially platelets—likely participate in COVID-19 pathogenesis. However, specific roles for platelets in COVID-19 as disease drivers, biomarkers, and therapeutic targets remain unspecified. Here, we highlight how platelets may be affected by COVID-19 in a manner supporting pathologic, immunologic, and inflammatory context. As such, mechanistic knowledge gaps around platelet function in COVID-19 represent an area of unmet clinical need, but also provide opportunities for studying platelet heterogeneity in a critically relevant inflammatory context.

Platelet Heterogeneity in Infection, Host Response, and COVID-19

Platelets are well known as specialized, peripheral blood cells essential to hemostasis and vascular health, but they also causally contribute to acute and chronic pathologies, including thrombosis and vascular inflammation.7 Translational efforts over the past decade, aiming to determine disease-specific platelet activities, have identified heterogeneous platelet phenotypes in the laboratory as well as in the clinic associated with inflammatory, thrombotic, and other conditions, including pathologies driven by a variety of viral infections.11–13 The mechanistic basis for how “proinflammatory,” “procoagulant,” and other potentially pathogenic platelet phenotypes come about remains vague. Consequently, efforts to develop effective therapeutic, diagnostic, and preventive strategies against maladaptive platelet mechanisms in thromboinflammatory pathologies remain delayed. As such, mechanistic knowledge gaps around platelet function in COVID-19 represent an area of unmet clinical need, but also provide opportunities for studying platelet heterogeneity in a critically relevant inflammatory context.

Heterogeneity in platelet phenotype as well as number (i.e., thrombocytopenia) are general hallmarks of viral infections, where a complex interplay between viral replication cycles, immune evasion, host response, and other mechanisms affect platelet function and turnover.14 Over the course of viral infection, interactions between platelet receptors and specific pathogen-associated molecular patterns (PAMPs) can promote platelet heterogeneity through innate immunity receptors, including toll-like receptors (TLRs), which sense PAMPs at the platelet plasma membrane or become activated in platelet endosomes upon PAMP internalization.15 For example, human cytomegalovirus directly binds to and activates platelets through TLR2 to promote inflammation and tissue injury.16 Likewise, following...
secretion into the bloodstream, the dengue virus nonstructural protein (NS1) triggers thromboinflammatory responses in a platelet TLR4-dependent manner.\(^{17}\) Currently, there is no evidence of SARS-CoV-2 sequestration or replication in megakaryocytes or platelets nor a widespread presence of SARS-CoV-2 nuclear acids or gene products in the circulation. However, SARS-CoV-2 N1 mRNA has been detected in platelets from a small number of COVID-19 patients (2/25 tested), despite no expression of the SARS-CoV-2 receptor ACE2 by platelets.\(^{18}\) Nonetheless, platelets are fully equipped to interact with and likely to internalize SARS-CoV-2 particles or components that may enter circulation in a manner relevant to the initial stages of infection, endothelial cell (EC) disruption, and COVID-19 pathogenesis, as recently detailed by Koupenova.\(^{19}\)

Severe SARS-CoV-2 infection is now characterized by a defective type 1 interferon (IFN) response, as well as an especially exaggerated production and secretion of interleukin (IL)-6 together with IL-1, IL-8, IFN-γ, tumor necrosis factor-α (TNF-α), and other immune modulators.\(^{20}\) This COVID-19 “cytokine storm” is suspected of obfuscating platelet function in a manner further promoting platelet heterogeneity, inflammation, and vascular dysfunction. As a key component of interest to COVID-19 pathology, IL-6 is already known to promote platelet activation in inflammatory contexts, but mechanisms underlying IL-6 platelet priming still remain unclear. For instance, while platelets express the IL-6 receptor subunit IL-6Rα (gp130), they do not express IL-6Rα and require exogenous addition of soluble sIL-6Rα to activate Jak/STAT and MAPK signaling ex vivo.\(^{21}\) In vivo, however, platelets may respond to IL-6 through interactions with leukocytes that bring IL-6Rα in close proximity to platelets in a manner related to models of platelet-leukocyte interactions in COVID-19 proposed by Merad and Martin,\(^{22}\) and that may be targeted by agents such as tocilizumab.\(^{23}\) Such mechanisms are supported by recent studies demonstrating upregulated MAPK signaling, and increased platelet reactivity and platelet-leukocyte aggregation in COVID-19 patients.\(^{18}\) An increased cross-talk between platelets and leukocytes has also been linked to other features of hypercoagulability in COVID-19 pathology, where platelet-monocyte aggregates fuel tissue factor (TF) expression, and platelet-neutrophil interactions contribute to microthrombosis and acute respiratory distress syndrome (ARDS).\(^{24,25}\)

Following cytokine storm and exacerbated inflammation, injured tissues may release damage-associated molecular patterns (DAMPs) into circulation,\(^{20}\) typically including high-mobility group box (HMGB1), S100 family, and histone proteins. DAMPs may be detected by innate immune receptors on platelets, including TLRs, to bring about platelet heterogeneity supporting inflammation, coagulation, and sepsis (\textit{\textgreater} Fig. 1). In addition to TLR responses, proteomics and clinical studies demonstrate robust complement system activation in severe platelet-related COVID-19 pathologies.\(^{26-29}\) Activation of complement receptor on platelets may prime specific platelet phenotypes and promote platelet-leukocyte interactions associated with microvascular thrombosis and platelet consumption in COVID-19.\(^{30,31}\) Antibody-mediated immune thrombocytopenia (ITP) mechanisms can also fuel platelet heterogeneity through platelet Fc receptor activation and platelet destruction in COVID-19.\(^{1,32}\)

Whether or not platelet heterogeneity and thrombocytopenia in severe COVID-19 follow from these innate and adaptive immune responses or an inhibition of platelet production remains to be clarified.\(^{31}\) Moreover, it remains to be determined whether restoring platelet counts in severe COVID-19 patients may help or hinder the host resolution of SARS-CoV-2 infection.\(^{31}\)

**Platelet Activation and Thrombosis in COVID-19**

Beyond interactions with circulating immune modulators and endogenous damage signals, factors from inflamed ECs also likely to encourage platelets to take on inflammatory phenotypes biased toward thrombosis in contexts such as COVID-19, especially if platelets and other immune cells are already primed by chronic disease.\(^{34,35}\) For instance, von Willebrand factor (VWF) expression and multimerization on ECs are generally associated with vascular inflammation,\(^{36}\) and VWF has been reported to be increased in COVID-19 in parallel with hypercoagulability and disease severity.\(^{37,38}\) Endothelial damage and vascular leakage also generally support platelet adhesion and activation through classical hemostatic responses to extracellular matrix molecules, where the platelet receptor GPVI rapidly activates platelet activation programs in response to collagen (\textit{\textgreater} Fig. 1).\(^{39}\) In addition to hemostatic interactions, platelets also interact directly with the endothelium and modulate the adhesion and infiltration of immune cells. For example, platelets play a fundamental role in regulating endothelial inflammation and permeability by synthesizing and secreting IL-1 to progress inflammatory diseases.\(^{40}\) Interestingly, proteomics studies have found upregulated, downregulated, and unaltered levels of several proteins known to be released by platelets in plasma and serum of COVID-19 patients in a manner reflective of disease severity.\(^{26,27}\) This seemingly differential platelet releasate in COVID-19 may be due to lower platelet counts or indicative of “exhausted” platelet phenotypes similarly found in other viral infection contexts.\(^{5}\) However, more specific mechanistic studies are needed to better determine whether and how platelet secretion may be altered in COVID-19.

The likely roles of platelet priming, heterogeneity, and (hyper)activation in COVID-19 suggest that antiplatelet agents may have protective effects or improve clinical outcomes in COVID-19. These possibilities have been extensively considered by several investigators, including Bikdeli et al and the Global COVID-19 Thrombosis Collaborative Group (\textit{\textgreater} Fig. 1).\(^{41}\) In addition to targeting inflammation or immune responses, several trials are now underway to determine whether and how aspirin, P2Y12 inhibitors (i.e., clopidogrel, ticagrelor), and other platelet-targeted agents may benefit COVID-19 patients. Some early, small-scale studies suggest that agents such as diprydamole may promote the clinical
recovery of severe COVID-19; however, other studies find no benefit for pretreatment with antiplatelet agents in severe cases of COVID-19, and large-scale extended trials are required to better understand the role of antiplatelet agents in COVID-19 as well as in vascular inflammation.

Many other agents that may specifically interfere with thromboinflammatory platelet responses are also of interest, including tyrosine kinase inhibitors that block platelet GPVI signaling (i.e., ibrutinib, acalabrutinib). Intrinsic and extrinsic coagulation pathways that regulate thrombin formation and promote procoagulant platelet phenotypes are also targets of interest in COVID-19.

Platelet Phenotype and Function in COVID-19 and Beyond

Interestingly, several COVID-19 comorbidities are already associated with platelet heterogeneity as well as poor outcomes in COVID-19, including metabolic syndrome, diabetes, gut dysbiosis, cardiovascular disease, cancer, and aging. Whether these conditions represent primed platelet states that may aggravate COVID-19 illness will become apparent as platelet activation mechanisms in inflammation and SARS-CoV-2 infection are further worked out. It is now recognized that alterations in platelet form and

---

**Fig. 1** Potential mechanisms contributing to platelet heterogeneity, inflammation, and thrombosis in coronavirus disease 2019 (COVID-19). Following SARS-CoV-2 infection through ACE2 receptors, endothelial cells may upregulate a variety of host responses (1), including secretion of ILs, chemokines, and DAMPs (2). Viral replication products may also be secreted into the circulation and act as PAMPs. Activated immune cells are also a source of ILs, chemokines, and DAMPs (3). These ligands may activate a variety of receptors on platelets, including TLR, CytR, and CheR. Immunity-associated pathways associated with the complement system are also evident in COVID-19, which may support platelet activation through CR on platelets (4). Other immune responses following FcγRIIA antibody ligation may also support platelet activation or platelet destruction and ITP. In this inflammatory context of COVID-19, platelets may more readily adhere to VWF on dysfunctional or damaged endothelium, which is likely upregulated in COVID-19 at sites of vascular leakage. After adhering to endothelial VWF through GPIb, platelets are readily activated by ECM proteins such as collagen, which can drive immunothrombosis through the immunotyrosine (ITAM) receptor GPVI. ADP secretion and thromboxane A2 (TxA2) synthesis amplify signaling events supporting platelet activation through TR and purinergic receptors (P2Y). Thrombin generation through TF pathways also supports the activation of PARs to establish procoagulant platelets that further progress thrombosis and fibrin formation (5). Immunothrombosis in COVID-19 may be further progressed by inflammatory factors secreted from platelets—including P-selectin, platelet factor 4 (PF4), CXCL4 RANTES (CCL5), IL-18, CD40L (CD154) and VEGF—to support platelet–leukocyte interactions as well as neutrophil extracellular traps (NETosis). Altogether, host immune responses and classic platelet hemostatic programs may come together and further fuel vascular inflammation, thrombosis, and mortality in COVID-19 through dysregulated platelet adhesion, secretion, integrin activation, and aggregation. Accordingly, platelet-directed drugs (i.e., aspirin, clopidogrel, dipyridamole, TKIs) may offer therapeutic options to dampen thrombus formation and improve outcomes in COVID-19. ACE2, angiotensin-converting enzyme 2; ADP, adenosine diphosphate; CheR, chemokine receptors; CR, complement receptor; CyR, cytokine receptors; DAMP, damage associated molecular pattern; ECM, extracellular matrix; FcγRIIA, Fc gamma receptor Ila; GP, glycoprotein; IL, interleukin; ITP, immune thrombocytopenia; PAMP, pathogen-associated molecular pattern; PAR, protease activated receptor; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TF, tissue factor; TKI, tyrosine kinase inhibitor; TR, thromboxane receptor; TLR, toll-like receptor; VWF, von Willebrand factor.
function can occur in a manner likely supporting specific disease states, however, it remains unclear how these changes come about in platelets at a molecular level in inflammatory diseases in general, and in specific cases such as COVID-19. To this end, quantitative phosphoproteomics profiling and pathway mapping may offer a means to define platelet phenotypes in specific contexts and collaborative efforts such as the COVID-19 Disease Map Initiative may help to specify molecular features of platelet phenotypes in COVID-19. Regardless of current and future prospects of defining biomarkers and platelet phenotypes specific to COVID-19, several lines of evidence point to platelets as important regulators of dysregulated inflammation and coagulation in COVID-19. Ongoing and future studies of platelets in inflammation and COVID-19 will better determine whether and how platelet function is beneficial and detrimental to, as well as informative of, disease progression and outcomes in SARS-CoV-2 infection.

Funding
This work is supported by the National Institutes of Health (grant R01HL146549).

Conflict of Interest
The authors report no conflicts of interest.

References
34 Matacic C. Blood vessel injury may spur disease’s fatal second phase. Science 2020;368(6495):1039–1040